Kala Bio (KALA) Change in Account Payables (2016 - 2026)
Kala Bio (KALA) posted Change in Account Payables of $58000.0 for Q1 2026, down 15.94% sequentially from $69000.0 in Q4 2025, and down 80.86% YoY from $303000.0 in Q1 2025.
Kala Bio (KALA) Change in Account Payables (2016 - 2026) Analysis & Trends
Kala Bio has reported Change in Account Payables for 11 years, with the latest figure at $58000.0 in Q1 2026.
- Quarterly Change in Account Payables fell 80.86% year-over-year to $58000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $113000.0 (down 43.22% YoY) and the FY2025 annual result came in at $358000.0, up 223.02% from the prior year.
- Change in Account Payables eased to $58000.0 in Q1 2026 per KALA's latest filing, from $69000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $4.4 million in Q2 2022 and troughed at -$4.5 million in Q4 2022.
- A 5-year average of -$226764.7 and a median of $27000.0 in 2023 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 33907.69% in 2022, down 342.06% in 2022.
- Over 5 years, Change in Account Payables stood at -$4.5 million in 2022, then soared by 102.93% to $132000.0 in 2023, then sank by 162.88% to -$83000.0 in 2024, then surged by 183.13% to $69000.0 in 2025, then slipped by 15.94% to $58000.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $58000.0, $69000.0, and $259000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | 58,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58,000.00 |
| Mar 31, 2026 | 58,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Sep 30, 2025 | 259,000.00 |
| Sep 30, 2025 | 259,000.00 |
| Jun 30, 2025 | -273,000.00 |
| Jun 30, 2025 | -273,000.00 |
| Mar 31, 2025 | 303,000.00 |
| Mar 31, 2025 | 303,000.00 |
| Dec 31, 2024 | -83,000.00 |
| Dec 31, 2024 | -83,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Jun 30, 2024 | -67,000.00 |
| Jun 30, 2024 | -67,000.00 |
| Mar 31, 2024 | -187,000.00 |
| Mar 31, 2024 | -187,000.00 |
| Dec 31, 2023 | 132,000.00 |
| Dec 31, 2023 | 132,000.00 |